The role of Rho-kinase pathway on PAH

Yoshihiro Fukumoto, Hiroaki Shimokawa

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


Anticoagulant agents, vasodilators, and lung transplantation are currently used for the treatment of pulmonary arterial hypertension (PAH); however, more effective treatment needs to be developed. Rho-kinase-mediated pathway plays an important role in various cellular functions, such as vascular smooth muscle hyperconstriction or cell adhesion and motility. We have demonstrated that Rho-kinase is activated in animal models of PAH associated with enhanced pulmonary vasoconstricting and proliferating responses, impaired endothelial vasodilator functions, and pulmonary remodeling and that intravenous fasudil, a selective Rho-kinase inhibitor, exerts acute pulmonary vasodilator effects in patients with severe PAH. Our findings indicate that Rho-kinase is a novel and important therapeutic target of PAH and that Rho-kinase inhibitors are a promising new class of drugs for the disorder.

Original languageEnglish
Pages (from-to)2091-2096
Number of pages6
JournalNippon rinsho. Japanese journal of clinical medicine
Issue number11
Publication statusPublished - 2008 Nov

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'The role of Rho-kinase pathway on PAH'. Together they form a unique fingerprint.

Cite this